MedTrace Logo

Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

NCT00484601 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-02-11

No results posted yet for this study

Summary

This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.

Conditions

  • Refractory Nasopharyngeal Carcinoma

Interventions

DRUG

Ifosfamide

DRUG

Doxorubicin

Sponsors & Collaborators

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Alex Chang, MD · Johns Hopkins Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-15
Primary Completion
2007-11-07
Completion
2007-11-07

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484601 on ClinicalTrials.gov